A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX872-B in Healthy Male and Female Subjects

Completed

• Conditions: Nephropathy; nierfalen; 10029149

• Registration Number: NL-OMON37040
• Lead Sponsor: Chemocentryx

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

healthy male or female
18 - 65 years inclusive
BMI 18 - 35 kg/m2 inclusive
non-smoker

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
Participation in another drug study within 60 days prior to randomization.
Any donation of blood(products) or significant blood loss within 56 dagen voor de keuring.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacodynamics:<br /><br>- Plasma levels of MCP-1 and possibly MCP-2, 3, 4 and other chemokines and<br /><br>cytokines related to CCR2 biology<br /><br>- Peripheral blood monocyte subset counts<br /><br>Pharmacokinetics: plasma/urine drug concentrations, pharmacokinetic parameters<br /><br>Safety: adverse events, vital signs, ECG-parameters, laboratory parameters,<br /><br>physical examination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>